相关临床试验
10
8 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
8
80.0%
招募中
2
20.0%
暂无批准数据
- The Alport syndrome market across the 7MM was valued at USD 27 million in 2025, with the United States accounting for approximately 88% of the total market share. - No therapies are currently approved specifically for Alport syndrome; standard care relies on ACE inhibitors, ARBs, and kidney transplantation for end-stage disease. - ENYO Pharma's vonafexor demonstrated positive Phase II ALPESTRIA-1 results in January 2026, showing slowed kidney function decline, with a Phase III trial planned for 2H 2026. - The pipeline includes diverse mechanisms such as ELX-02 for nonsense mutations, setanaxib (NOX1/4 inhibitor), and BAY3401016 (anti-Sema3A monoclonal antibody), with total prevalent cases estimated at ~203,800 in the 7MM in 2025.
- DelveInsight's 2025 pipeline report reveals over 25 companies are actively developing 30+ therapeutic candidates for IgA nephropathy treatment, spanning multiple clinical and preclinical stages. - Novartis achieved significant regulatory milestones with FDA approvals for Vanrafia (atrasentan) in April 2025 and accelerated approval for Fabhalta (iptacopan) in August 2024, both targeting proteinuria reduction. - Key pipeline candidates include Chinook Therapeutics' atrasentan in Phase III trials, Guangdong Hengrui's SHR-2010 in Phase II, and Takeda's TAK-079 in Phase 1b development. - The market growth is driven by rising disease prevalence, improved diagnostic capabilities, and substantial unmet medical needs as many patients progress to end-stage renal disease.
- Primary hyperoxaluria pipeline features over 6 companies developing more than 6 therapeutic candidates, with notable advances in gene editing and RNA interference therapies. - Arbor Biotechnologies achieved a significant milestone in July 2025 with the first patient treated in their Phase 1/2 redePHine trial for ABO-101, a gene-editing therapy for PH1. - The FDA has approved two breakthrough therapies: nedosiran (Rivfloza) in September 2023 for PH1 patients with preserved kidney function, and lumasiran in November 2020 for both adults and children. - Leading pipeline candidates include CHK-336, BBP-711, BMN 255, Oxabact, and Nedosiran, spanning various development stages from preclinical to Phase III trials.
- Frazier Healthcare Partners has successfully closed a $1.3 billion venture capital fund specifically targeting early-stage biotechnology companies and startup creation. - The firm was one of the most active biotech investors in 2024, participating in 17 deals and leading nearly one-third of those transactions. - Recent successful exits include Scorpion Therapeutics' $2.5 billion drug sale to Eli Lilly and major acquisitions like Novartis' $3.5 billion purchase of Chinook Therapeutics. - The new fund launch comes amid declining biotech venture funding, which dropped from $7 billion to $4.8 billion in Q2 2025 according to HSBC Innovation Banking.
• Vivo Capital has closed the third cycle of its Opportunity Fund with over $740 million in commitments, focusing on preclinical and clinical-stage life sciences companies developing novel therapies. • The fund has previously backed companies that achieved significant milestones, including FDA approvals for treatments targeting COPD, myelodysplastic syndrome, narcolepsy, and Prader-Willi Syndrome. • Several Vivo-backed companies have been acquired by pharmaceutical giants in billion-dollar deals, including RayzeBio (Bristol-Myers Squibb, $4.1B), Chinook Therapeutics (Novartis, $3.2B), and Sierra Oncology (GSK, $1.9B).
- DelveInsight's 2025 pipeline analysis reveals over 30 companies developing 30+ therapies for IgA nephropathy treatment, representing a robust therapeutic landscape. - The global IgA nephropathy market reached approximately $500 million in 2022, with the US accounting for $160 million, and is projected to grow through 2034. - Recent regulatory milestones include Novartis receiving FDA priority review for iptacopan based on positive Phase III results and Vera Therapeutics obtaining breakthrough therapy designation for atacicept. - Key pipeline therapies span multiple mechanisms including complement inhibitors, endothelin receptor antagonists, and B-cell targeting agents across various development phases.
- Purespring Therapeutics has secured $105 million in Series B funding to advance its lead candidate, PS-002, a gene therapy for IgA nephropathy (IgAN). - PS-002 is an adeno-associated viral (AAV) gene therapy designed to target podocytes, specialized kidney cells, aiming to reduce inflammation and kidney dysfunction in IgAN patients. - The funding will support the launch of a Phase I/II clinical trial for PS-002, addressing the critical unmet need for effective treatments beyond dialysis and transplantation in chronic kidney disease. - Purespring's platform, FunSel, identifies effective treatments from a library of AAV vectors, showcasing potential for treating various kidney diseases by targeting specific genes.
